ViiV Healthcare is beginning Phase III trials of the integrase inhibitor Tivicay (dolutegravir) and the non-nucleoside reverse transcriptase inhibitor (NNRTI or non-nuke) Edurant (rilpivirine) to treat HIV among those switching from another stable drug regimen. If successful, the trial could lead to the first two-drug (as opposed to the standard three- or four-drug) HIV regimen. The study is giving participants the pair of antiretrovirals as individual tablets while separate research develops the medications as components of a fixed-dose combination tablet. The researchers will primarily look at the proportion of participants with a fully suppressed viral load after 48 weeks of treatment. They will also determine rates of viral resistance among participants and the safety and tolerability of the regimen, as well as shifts in indicators of kidney, bone and cardiovascular health.